CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer

Purpose: Although elevated proportions of CD4+CD25+ regulatory T (Treg) cells have been shown in several types of cancers, very little is known about the existence and function of CD8+ Treg cells in prostate cancer. In this study, we investigated prostate tumor–derived CD8+ Treg cells and their function. Experimental Design: Tumor-infiltrating lymphocytes (TIL) from fresh tumor specimens of patients with prostate cancer were generated and subjected to phenotypic and suppressive function analyses. In particular, we investigated the role and function CD8+ Treg cells in prostate cancer. Results: We show that high percentages of CD4+CD25+ T cells are probably present in the majority (70%) of prostate TILs. Remarkably, both CD4+ and CD8+ T-cell subpopulations possessed potent suppressive activity. T-cell cloning and fluorescence-activated cell sorting analyses showed the presence of CD8+CD25+ Treg cell clones that expressed FoxP3 and suppressed naïve T-cell proliferation, in addition to the previously known CD4+CD25+ Treg cells. These CD8+ Treg cells suppressed naïve T-cell proliferation mainly through a cell contact–dependent mechanism. Importantly, the suppressive function of CD8+ Treg cells could be reversed by human Toll-like receptor 8 (TLR8) signaling. Conclusion: Our study shows that like CD4+CD25+ Treg cells, CD8+ Foxp3+ Treg cells present in prostate tumor–derived TILs suppress immune responses and that their suppressive function can be regulated by TLR8 ligands, raising the possibility that the manipulation of Treg cell function by TLR8 ligands could improve the efficacy of immunotherapy for prostate cancer patients.

[1]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[2]  S. Slovin.  Emerging role of immunotherapy in the management of prostate cancer. , 2007, Oncology.

[3]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[5]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[6]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.

[7]  E. Shevach,et al.  Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[8]  E. Small,et al.  Immunotherapy for prostate cancer , 2006, Current urology reports.

[9]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[10]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[11]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[12]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[13]  T. Curiel,et al.  Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. , 2005, Cancer research.

[14]  Fiona Powrie,et al.  Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.

[15]  W. Isaacs,et al.  Prostate carcinogenesis and inflammation: emerging insights. , 2005, Carcinogenesis.

[16]  A. Rudensky,et al.  Foxp 3 programs the development and function of CD 4 + CD 25 + regulatory T cells , 2003 .

[17]  L. Cosmi,et al.  Human CD 8 CD 25 thymocytes share phenotypic and functional features with CD 4 CD 25 regulatory thymocytes , 2003 .

[18]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[19]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[20]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[21]  Rong-Fu Wang.  Functional control of regulatory T cells and cancer immunotherapy. , 2006, Seminars in cancer biology.

[22]  M. Matyszak,et al.  Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function , 2005, European journal of immunology.

[23]  F. Liew,et al.  Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  鬼塚 正三郎.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .

[25]  S. Ziegler.  FOXP3: of mice and men. , 2006, Annual review of immunology.

[26]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[27]  A. Banham,et al.  CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1 , 2006, The Journal of Immunology.

[28]  C. Helgason,et al.  Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. , 2005, Cancer research.

[29]  Weiyi Peng,et al.  Toll-Like Receptor 8-Mediated Reversal of CD4+ Regulatory T Cell Function , 2005, Science.

[30]  L. Cosmi,et al.  Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. , 2003, Blood.

[31]  G. Coukos,et al.  Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 , 2001 .

[32]  Y. Kawamoto,et al.  Essential Roles of CD8+CD122+ Regulatory T Cells in the Maintenance of T Cell Homeostasis , 2004, The Journal of experimental medicine.

[33]  L. Chess,et al.  The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. , 2000, Annual review of immunology.

[34]  E. Shevach,et al.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.

[35]  H. Stein,et al.  Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. , 2006, European journal of immunology.

[36]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[37]  C. Bécourt,et al.  Peripheral CD8+CD25+ T Lymphocytes from MHC Class II-Deficient Mice Exhibit Regulatory Activity1 , 2005, The Journal of Immunology.

[38]  L. Chess,et al.  An integrated view of suppressor T cell subsets in immunoregulation. , 2004, The Journal of clinical investigation.

[39]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[40]  Rong-Fu Wang.  Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II‐restricted tumor antigens , 2002, Immunological reviews.

[41]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[42]  Linrong Lu,et al.  Qa-1 restriction of CD8+ suppressor T cells. , 2004, The Journal of clinical investigation.

[43]  Clare Baecher-Allan,et al.  Immune regulation in tumor-bearing hosts. , 2006, Current opinion in immunology.

[44]  S. Rosenberg,et al.  Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.

[45]  Helen Y Wang,et al.  Regulatory T cells and Toll-like receptors in tumor immunity. , 2006, Seminars in immunology.

[46]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  G. Vlad,et al.  License to Heal: Bidirectional Interaction of Antigen-Specific Regulatory T Cells and Tolerogenic APC , 2005, The Journal of Immunology.

[48]  L. Joosten,et al.  Toll-like receptor 2 controls expansion and function of regulatory T cells. , 2006, The Journal of clinical investigation.

[49]  L. Sugar.  Inflammation and prostate cancer. , 2006, The Canadian journal of urology.

[50]  M. Schilham,et al.  Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. , 2005, Human immunology.

[51]  D. McNeel,et al.  Immune-based therapies for prostate cancer. , 2005, Immunology letters.

[52]  H. Wagner,et al.  Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 , 2002, Nature Immunology.